Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.8
Journals
Current Oncology
Announcements
share announcement

Announcements

20 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Health Economics”

As Current Oncology (ISSN: 1718-7729) is of an open-access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Health Economics” listed below:

1. “Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients”
by Yuti P. Patel, Donald Husereau, Natasha B. Leighl, Barbara Melosky and Julian Nam
Curr. Oncol. 2021, 28(6), 5278–5294; https://doi.org/10.3390/curroncol28060441
Available online: https://www.mdpi.com/1718-7729/28/6/441

2. “Cost Analysis of Laparoscopic Low Anterior Resection vs. Transanal Endoscopic Microsurgery for Rectal Neoplasms”
by Katerina Neumann, Nirmal Randhawa, Jason Park and David J. Hochman
Curr. Oncol. 2021, 28(3), 1795–1802; https://doi.org/10.3390/curroncol28030167
Available online: https://www.mdpi.com/1718-7729/28/3/167

3. “The Out-of-Pocket Cost Burden of Cancer Care—A Systematic Literature Review”
by Nicolas Iragorri, Claire de Oliveira, Natalie Fitzgerald and Beverley Essue
Curr. Oncol. 2021, 28(2), 1216–1248; https://doi.org/10.3390/curroncol28020117
Available online: https://www.mdpi.com/1718-7729/28/2/117

4. “Cost Minimization Analysis of Hypofractionated Radiotherapy”
by Hannah L.Yaremko, Gordon E. Locke, Ronald Chow, Michael Lock, Robert Dinniwell and Brian P. Yaremko
Curr. Oncol. 2021, 28(1), 716–725; https://doi.org/10.3390/curroncol28010070
Available online: https://www.mdpi.com/1718-7729/28/1/70

5. “Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care”
by Adam J. N. Raymakers, David Cameron, Scott Tyldesley and Dean A. Regier
Curr. Oncol. 2021, 28(3), 1857–1866; https://doi.org/10.3390/curroncol28030172
Available online: https://www.mdpi.com/1718-7729/28/3/172

6. “Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs”
by Ronak Saluja, Tina Jiao, Liza Koshy, Matthew Cheung and Kelvin K. W. Chan
Curr. Oncol. 2021, 28(1), 606–618; https://doi.org/10.3390/curroncol28010060
Available online: https://www.mdpi.com/1718-7729/28/1/60

7. “Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer”
by Megan M. Tu, Mark Clemons, Carol Stober, Ahwon Jeong, Lisa Vandermeer, Mihaela Mates, Phillip Blanchette, Anil Abraham Joy, Olexiy Aseyev, Gregory Pond et al.
Curr. Oncol. 2021, 28(3), 1847–1856; https://doi.org/10.3390/curroncol28030171
Available online: https://www.mdpi.com/1718-7729/28/3/171

8. “Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial”
by Anca Prica, Annette E. Hay, Michael Crump, Nicole Mittmann, Lois E. Shepherd, Ralph M. Meyer, Kevin I. Imrie, Nancy Risebrough, Marina Djurfeldt, Bingshu E. Chen et al.
Curr. Oncol. 2021, 28(2), 1256–1261; https://doi.org/10.3390/curroncol28020119
Available online: https://www.mdpi.com/1718-7729/28/2/119

More News...
Back to TopTop